Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.49 |
| ▸ | INSR | P06213 | 4/20 | 0.49 |
| ▸ | IGF1R | P08069 | 4/20 | 0.49 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.45 |
| ▸ | ROS1 | P08922 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | MET | P08581 | 3/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.42 |
| ▸ | CDK7 | P50613 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062041 | 0.87 | ALK (0.55) | ALKINSRIGF1RZAP70ROS1 | |
| SCHEMBL2062634 | 0.87 | ALK (0.44) | ALKINSRIGF1RZAP70LRRK2 | |
| SCHEMBL2062043 | 0.85 | ZAP70 (0.46) | ALKINSRIGF1RZAP70LRRK2 | |
| SCHEMBL602789 | 0.85 | EGFR (0.48) | ALKLRRK2ROS1EGFRMET | |
| SCHEMBL31664180 | 0.85 | EGFR (0.48) | ALKLRRK2ROS1EGFRMET | |
| SCHEMBL30659886 | 0.85 | EGFR (0.48) | ALKLRRK2ROS1EGFRMET | |
| SCHEMBL26906847 | 0.85 | EGFR (0.48) | ALKLRRK2ROS1EGFRMET | |
| SCHEMBL23932944 | 0.83 | ALK (0.50) | ALKINSRIGF1RZAP70LRRK2 | |
| SCHEMBL23933090 | 0.82 | EGFR (0.45) | ALKINSRIGF1RZAP70LRRK2 | |
| SCHEMBL2061300 | 0.81 | GAA (0.60) | ALKINSRIGF1RLRRK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2021216440-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | ERBB2, ALK, ERBB3 | ALK 2/4885INSR 1617/4885IGF1R 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.